期刊: LIVER CANCER, 2022; 11 (2)
Hepatocellular carcinoma (HCC) ranks the third place among all causes inducing cancer-associated mortality, worldwide. HCC nearly exclusively occurs i......
期刊: LIVER CANCER, 2022; 11 (4)
Introduction: Although microwave ablation (MWA) is a promising technique for hepatocellular carcinoma (HCC) treatment, its 10-year efficacy is unknown......
期刊: LIVER CANCER, 2022; 11 (3)
Background: Tumor recurrence is an abomination for hepatocellular carcinoma (HCC) patients receiving local treatment. Purpose: The aim of the study wa......
期刊: LIVER CANCER, 2022; 11 (4)
Introduction: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma (HCC). We aimed to compare the clinical outcomes of lenvati......
期刊: LIVER CANCER, 2022; 11 (3)
Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and causes many cancer-related deaths worldwide; in China, it is th......
期刊: LIVER CANCER, 2022; 11 (5)
Introduction: This investigator-initiated clinical trial aims to study the efficacy and safety of administering selective internal radiation therapy w......
期刊: LIVER CANCER, 2022; 11 (5)
Background: Asia has a high burden of hepatocellular carcinoma (HCC) due to the high rates of chronic hepatitis B infection and accounts for 70% of HC......
期刊: LIVER CANCER, 2022; 11 (4)
Portal vein tumor thrombus (PVTT) is very common and it plays a major role in the prognosis and clinical staging of hepatocellular carcinoma (HCC). We......
期刊: LIVER CANCER, 2021; 10 (3)
Introduction: KEYNOTE-240 investigated the efficacy and safety of pembrolizumab plus best supportive care (BSC) in sorafenib-treated patients with adv......
期刊: LIVER CANCER, 2021; 10 (3)
Background: Most phase 3 clinical trials of systemic therapy for first-line unresectable hepatocellular carcinoma (HCC) have failed, with the exceptio......
期刊: LIVER CANCER, 2021; 10 (3)
Introduction: Real-world management of patients with hepatocellular carcinoma (HCC) is crucially challenging in the current rapidly evolving clinical ......
期刊: LIVER CANCER, 2021; 10 (4)
Introduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib in patie......
期刊: LIVER CANCER, 2021; 10 (3)
Introduction: Perihilar cholangiocarcinoma (pCCA) is a biliary tract cancer with a dismal prognosis, with surgery being the only chance of cure. A cha......
期刊: LIVER CANCER, 2021; 10 (4)
Background: Reversal of CD8 T-cell exhaustion was considered a major antitumor mechanism of anti-programmed cell death-1 (PD-1)/ anti-programmed death......